- Home
- KZIA vs MBIO Comparison
KZIA vs MBIO Comparison
Compare KZIA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- MBIO
- Stock Information
- Founded
- KZIA 1994
- MBIO 2015
- Country
- KZIA Australia
- MBIO United States
- Employees
- KZIA N/A
- MBIO 80
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- MBIO Health Care
- Exchange
- KZIA Nasdaq
- MBIO Nasdaq
- Market Cap
- KZIA 7.8M
- MBIO 7.3M
- IPO Year
- KZIA 1999
- MBIO N/A
- Fundamental
- Price
- KZIA $1.42
- MBIO $5.55
- Analyst Decision
- KZIA Strong Buy
- MBIO Strong Buy
- Analyst Count
- KZIA 1
- MBIO 1
- Target Price
- KZIA $20.00
- MBIO $2.00
- AVG Volume (30 Days)
- KZIA 116.4K
- MBIO 468.6K
- Earning Date
- KZIA 11-15-2024
- MBIO 03-10-2025
- Dividend Yield
- KZIA N/A
- MBIO N/A
- EPS Growth
- KZIA N/A
- MBIO N/A
- EPS
- KZIA N/A
- MBIO N/A
- Revenue
- KZIA $1,655,324.00
- MBIO N/A
- Revenue This Year
- KZIA $806.89
- MBIO N/A
- Revenue Next Year
- KZIA N/A
- MBIO N/A
- P/E Ratio
- KZIA N/A
- MBIO N/A
- Revenue Growth
- KZIA 248000.00
- MBIO N/A
- 52 Week Low
- KZIA $1.39
- MBIO $5.19
- 52 Week High
- KZIA $15.80
- MBIO $76.00
- Technical
- Relative Strength Index (RSI)
- KZIA 20.74
- MBIO 31.43
- Support Level
- KZIA $1.42
- MBIO $5.19
- Resistance Level
- KZIA $1.89
- MBIO $13.30
- Average True Range (ATR)
- KZIA 0.24
- MBIO 2.31
- MACD
- KZIA 0.02
- MBIO -0.47
- Stochastic Oscillator
- KZIA 1.40
- MBIO 2.14
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.